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Abstract
PURPOSE: Tumor cell migration and metastasis share many similarities with leukocyte trafficking, which is critically
regulated by chemokines and their receptors. CXCR4 is the most widely expressed chemokine receptor in many
different types of cancer and has been linked to tumor dissemination and poor prognosis. Several CXCR4 antago-
nists have been synthesized. A totally novel approach to discover chemokine receptor antagonists is the use of
bacteria. Bacteria produce chemokine receptor inhibitors to prevent neutrophil extravasation and migration toward
the infection site to escape clearance by innate immune cells. The aim of the current study was to find and identify
the mechanism of a bacterial protein that specifically targets CXCR4, a chemokine receptor shared by neutrophils
and cancer cells. EXPERIMENTAL DESIGN: Several staphylococcal proteins were screened for their capacity to pre-
vent binding of a function-blocking antibody against CXCR4. RESULTS: Staphylococcal superantigen-like 10 was
found to bind CXCR4 expressed on human T acute lymphoblastic leukemia, lymphoma, and cervical carcinoma cell
lines. It potently inhibited CXCL12-induced calcium mobilization and cell migration. CONCLUSIONS: Staphylococcal
superantigen-like 10 is a potential lead in the development of new anticancer compounds preventing metastasis by
targeting CXCR4.
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Introduction
Metastasis is one of the main hallmarks of cancer and the mechanism
responsible for mortality observed for many cancers. The control of
metastasis is critical for the control of cancer progression. In addition
to cytotoxic and targeted therapies, drugs that target receptors on ma-
lignant cells responsible for their metastasizing capacity would be of
great value for treatment of most cancers.
In the recent years, striking similarities between leukocyte traffick-
ing and tumor cell migration revealed that they are both critically
regulated by chemokines and their receptors [1]. Bacteria are natural
producers of chemokine receptor inhibitors that prevent leukocyte
migration toward the site of infection. These evolutionary tailored bac-
terial proteins can be explored for their capacity to antagonize chemo-
kine receptors that play a role in malignant cell behavior as well.
Tumor cells express functional chemokine receptors to sustain pro-
liferation, angiogenesis, and survival and to promote organ-specific
localization of distant metastases [2,3]. Increasing evidence suggests
the pivotal role of the chemokine stromal cell–derived factor 1
(CXCL12/SDF-1α) and its CXCR4 in the regulation of growth of
both primary and metastatic cancers [1,4,5]. CXCR4 is involved in
the dissemination of breast cancer, of prostate cancer to the bone
marrow [6], of colon cancer to the liver [7], and of undifferentiated
thyroid cancer [8]. CXCR4 is highly expressed in human breast
cancer cells and metastases. The specific ligand CXCL12/SDF-1α
exhibits peak levels of expression in organs representing the first
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destination of breast cancer metastasis. In vivo, neutralizing the inter-
actions of CXCL12 and CXCR4 significantly impairs metastasis of
breast cancer cells to regional lymph nodes and the lungs [9].
CXCR4 expression is associated with cervical adenocarcinoma cell
migration and proliferation, and primary cervical adenocarcinoma
cells expressing CXCR4 are significantly more likely to metastasize
to pelvic lymph nodes [10]. Myeloid and lymphoid leukemia cells
express high levels of CXCR4 that plays a critical role in leukemia
cell chemotaxis and migration into bone marrow stroma [11–13].
In vitro, CXCR4 antagonists strongly inhibit migratory and signaling
responses to CXCL12 and partially antagonize the protective effects
of marrow stromal cells to spontaneous or drug-induced apoptosis of
chronic lymphocytic leukemia, acute lymphocytic leukemia (ALL),
and acute myeloid leukemia cells [14–16]. CXCR4 expression levels
have a major prognostic impact in acute myeloid leukemia [17].
CXCR4 is expressed by primary T-ALL cells of patients with child-
hood T-ALL [18], and a high CXCR4 expression predicts extra-
medullary organ infiltration in childhood [19]. Promising results in
preclinical tumor models indicate that CXCR4 antagonists may have
additional value to conventional cytotoxic therapy in patients with
various malignancies and immune diseases.
For more than a century, bacterial products have been used for
the treatment of cancer [20]. Bacteria produce proteins that target
chemokine and other chemoattractant receptors to prevent leuko-
cyte migration. We have described chemotaxis inhibitory protein
of Staphylococcus aureus (CHIPS), an excreted virulence factor of
S. aureus [21]. CHIPS is known to inhibit formylated peptides
and complement factor C5a–induced responses in neutrophils
through direct binding to the formyl peptide receptor (FPR) and
C5a receptor (C5aR), respectively [22–24]. Thereby, CHIPS inhibits
the initial activation and migration of neutrophils to the site of in-
fection, and thus, it hampers the clearance of S. aureus by innate im-
mune cells. Recently, the structure of CHIPS was resolved, and it
revealed homology to the C-terminal domain of staphylococcal
superantigen-like 5 and 7 (SSL5 and SSL7) [25]. SSLs are a family
of secreted proteins identified through sequence homology to staphy-
lococcal and streptococcal superantigens, and although structurally
related, they do not show superantigenic properties.
The aim of this study was to find a bacterial protein targeting
CXCR4 that can prevent malignant cell behavior. Therefore, we
screened several staphylococcal proteins for their ability to inter-
fere with a function-blocking antibody directed against CXCR4.
We identified SSL10 binding to CXCR4, and SSL10 inhibited
the CXCL12-induced migration of a human leukemia ( Jurkat) cell
line. In addition, migration of the cervical carcinoma cell line HeLa
toward CXCL12 was strongly inhibited by SSL10. Inhibition of
CXCR4 by SSL10 is a new and attractive prospective into the
molecular mechanism of human leukemia, lymphoma, and solid
cancer metastases.
Materials and Methods
Reagents
Monoclonal antibodies (mAbs) directed against CXCR4 (clone
12G5), CXCR1 (clone 42705), CXCR7 (clone 11G8), and C5aR
were purchased from BD (San Jose, CA), R&D Systems (Minneapolis,
MN), and HBT (Uden, the Netherlands), respectively. Fluorescein
isothiocynate (FITC)–conjugated mAb directed against CD3 and goat
antimouse (Fc-specific)–FITC and goat antimouse (Fc-specific)–PE
were from Dako (Carpinteria, CA). Synthetic human CXCL12 and
CXCL8 were purchased from Peprotech (Rocky Hill, NJ), and C5a
was obtained from Sigma-Aldrich (St. Louis, MO). Anti-HIS antibody
was obtained from Novagen (Darmstadt, Germany). Goat antimouse
horseradish peroxidase conjugate (GAM-HRP) was from Southern
Biotech (Birmingham, AL). Antibodies against phosphoprotein ki-
nase B/Akt and protein kinase B/Akt were purchased from Cell
Signaling Technology (Leiden, the Netherlands). AMD3100, a small-
molecule CXCR4 antagonist, was purchased from Sigma.
Cells
The human Jurkat T cell ALL, SupT1 T cell lymphoblastic lym-
phoma (ATCC, Rockville, MD) and A2780 ovarian carcinoma (ob-
tained from Dr. R. Ozols, Philadelphia, PA) cell lines were grown
in RPMI-1640 medium supplemented with 10% fetal calf serum
(FCS), 10 μg/ml gentamicin, and L-glutamine. The cervical carci-
noma cell line HeLa (ATCC) was grown in DMEM/HAM’s F12,
1:1 with 10% FCS. All cell lines were kept at 37°C in a humidified
atmosphere consisting of 95% air and 5% CO2. HEK293EBNA1
cells were maintained in suspension in Freestyle expression medium
(Invitrogen, Life Technologies, Paisley, United Kingdom) supplemented
with 0.2% FCS and 50 μg/ml G418 (Invitrogen). Twenty-four hours
before transfection, cells were seeded to 3 × 105 cells/ml in Freestyle
expression medium containing 0.05% FCS. Three hours after transfec-
tion, 0.9% of primatone (Kerry Bio-science, Almere, the Netherlands)
was added.
For leukocyte isolation, heparinized blood was diluted with an
equal volume of PBS and subsequently layered onto a gradient of
Ficoll-Paque PLUS (Amersham Biosciences, Piscataway, NJ) and
Histopaque 1119 (Sigma-Aldrich). After centrifugation for 20 minutes
at 400g, neutrophils were collected from the Histopaque layer. After
washing with RPMI-1640 containing 25 mM HEPES, L-glutamine
(BioWhittaker, Walkersville, MD), and 0.05% human serum albumin
(HSA; Sanquin, Amsterdam, the Netherlands) (RPMI/HSA), the
neutrophils were subjected to a hypotonic shock with water for 30 sec-
onds to lyse the remaining erythrocytes and were washed. Informed
consent was obtained from all subjects and was provided in accor-
dance with the Declaration of Helsinki. Approval was obtained from
the medical ethics committee of the University Medical Center Utrecht
(Utrecht, the Netherlands).
Cloning, Expression, and Purification of SSL10
For the expression of recombinant SSL10 (protein identity
YP_498982.1), the SSL10 gene (genomic locus tag SAOUHSC_00395)
of S. aureus strain NCTC8325, (minus signal sequence coding for
the first 30 amino acids) was cloned into the expression vector
pRSETB (Invitrogen) directly downstream of the enterokinase (EK)
cleavage site (Figure 1A). For this purpose, an overhang extension po-
lymerase chain reaction (PCR) was performed. First, we amplified
(PCR1) the HIS-tag and EK cleavage site from the pRSETB vector
using the XbaI recognition sequence (underlined) primer 1: 5′
GCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAG3′) and
introducing the N-terminal first 29-bp sequence of the SSL10 gene
through the reverse primer (primer 2: 5′TGTTTATTTACTGACTT-
TTGATTTTGTTTCTTGTCGTCATCGTCGTACAG3′). Second,
the SSL10 gene was amplified by PCR2 (primer 3: 5′AAACAAAAT-
CAAAAGTCAGTAAATAAAC3′, primer 4: 5′GCCGAATTCT-
TACTTTAAGTTAACTTCAATATC3′) on chromosomal DNA of
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S. aureus strain NCTC8325 introducing an EcoRI cleavage site (un-
derlined). Finally, a third PCR (PCR3) was performed on a mixture
of PCR1 and PCR2 to anneal the two PCR products together using
primers 1 and 4. All PCR products were amplified using PfuTurbo
DNA polymerase (Stratagene, Cedar Creek, TX). PCR3 was then di-
gested with XbaI and EcoRI and ligated into the XbaI and EcoRI sites
of the pRSETB vector. After verification of the correct sequence, the
pRSET/SSL10 expression vector was transformed in BL21(DE3)
Escherichia coli according to the manufacturer’s protocol (Novagen).
Expression of histidine-tagged SSL10 (HIS-SSL10) was induced with
1 mM isopropyl-β-D-thiogalactopyranoside (IPTG; Roche, Basel,
Switzerland) for 3 hours. To check for proper E. coli expression of
HIS-SSL10, 20 μl of E. coli culture before and 3 hours after induction
by IPTG was treated with sample buffer and run on sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE). Analysis of
the presence of HIS-SSL10 was performed by Coomassie brilliant
blue staining and enhanced chemiluminescence (Amersham Biosci-
ences) Western blot analysis using 1 μg/ml anti-HIS mAb and an
HRP-conjugated secondary antibody (Figure 1B). HIS-tagged SSL10
was isolated under denaturing conditions on a HiTrap chelating HP
column according to the manufacturer’s protocol (Amersham Bio-
sciences). The protein was renatured on the column by gradually ex-
changing a denaturing buffer (8 M urea, 500 mM NaCl, 500 mM
sodium phosphate buffer, pH 5.3) for the native buffer (500 mM
NaCl, 500 mM sodium phosphate buffer, pH 5.3). Bound protein
was eluted using 50 mM ethylenediaminetetraacetic acid. After di-
alysis, the HIS-tag was removed from SSL10 by cleavage with EK
according to the manufacturer’s instructions (Invitrogen Life Technol-
ogies). Finally, SSL10 was stored in PBS, and its purity was examined
by SDS-PAGE (Figure 1B). SSL6, SSL7, SSL8, and SSL11, all from
S. aureus NTCT8325 (respective protein identities: YP_498978.1,
YP_498979.1, YP_498980.1, and YP_498983.1), were also cloned
and expressed in the pRSET B vector similarly as described for SSL10.
CHIPS, staphylococcal complement inhibitors (SCIN, SCIN-B, and
SCIN-C), Orf-D, and FPRL1 inhibitory protein (FLIPr) were expressed
as previously described [21,26–28].
SSL10 Binding to CXCR4-Expressing Cells
To determine binding of SSL10 to the CXCR4-expressing cell
lines Jurkat and SupT1, SSL10 was labeled with FITC. Therefore,
1 mg/ml SSL10 was incubated with 100 μg/ml FITC in 0.1 M so-
dium carbonate buffer (pH 9.6) for 1 hour at 37°C. FITC-labeled
SSL10 (SSL10-FITC) was separated from unbound FITC using a
HiTrap desalting column (Amersham Biosciences). For binding of
SSL10-FITC to cells, Jurkat and SupT1 cells (5 × 106 cells/ml) were
incubated with increasing concentrations of SSL10-FITC in RPMI/
HSA for 30 minutes on ice. After washing, fluorescence was measured
on a flow cytometer (FACSCalibur; Becton Dickinson, Franklin
Lanes, NJ). To examine the role of sialic acids in the SSL10/CXCR4
interaction, Jurkat and SupT1 cells (5 × 106 cells/ml) were first treated
with 0.2 U/ml neuraminidase (from Clostridium perfringens; Roche
Diagnostics, Almere, the Netherlands) at 37°C for 45 minutes in
RPMI/HSA before incubating with SSL10. To study the internal-
ization of SSL10, trypan blue quenching was used as described by
Postma et al. [23]. Jurkat cells at 5 × 106 cells/ml were incubated with
10 μg/ml SSL10-FITC in RPMI/HSA at 37°C. At different time
points, the SSL10-FITC binding was measured in a flow cytometer,
before and immediately after addition of 300 μg/ml trypan blue
(Merck, Darmstadt, Germany), to discriminate between cell surface–
bound and internalized ligand.
Competition between SSL10 and Antibody Binding to CXCR4
and CXCR7
To determine whether staphylococcal proteins were able to bind
CXCR4 and compete with anti-CXCR4 monoclonal antibody
(mAb) binding, Jurkat and SupT1 cells (5 × 106 cells/ml) were incu-
bated with 0 to 10 μg/ml SSL10 for 30 minutes on ice in RPMI/
HSA. After washing, anti-CXCR4 mAb clone 12G5 was added for
Figure 1. Cloning, expression, and isolation of SSL10. (A) Schematic overview of the cloning and expression procedure of HIS-SSL10.
See Materials and Methods for clarification of PCR and primer use. After isolation of HIS-SSL10, the HIS-tag is removed by EK cleavage,
resulting in the SSL10 protein of 23.1 kDa as excreted by S. aureus strain NCTC8325. (B) Detection of HIS-SSL10 expression in and
isolation from BL21(DE3) E. coli. Lanes 1 to 4 represent Coomassie brilliant blue staining of HIS-SSL10 expression before (lane 1)
and after 3 hours of IPTG induction (lane 2), HIS-SSL10 after isolation by nickel affinity chromatography (lane 3), and the final SSL10
product after EK cleavage (lane 4). Lane 5 represents the expression of HIS-SSL10 detected by Western blot analysis using an anti-HIS
mAb and GAM-HRP.
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30 minutes on ice. Anti-CD3 mAb was used as a control mAb on
Jurkat cells. Anti-CXCR1 and anti-C5aR mAbs were used as con-
trol mAbs on human neutrophils. mAbs were detected with FITC-
conjugated goat antimouse immunoglobulin G (IgG). After washing,
antibody binding was analyzed using flow cytometry. Similar experi-
ments with HeLa cells were performed to test binding of anti-
CXCR4 mAb clone 12G5 and anti-CXCR7 mAb clone 11G8; mAbs
were detected with PE-conjugated goat antimouse IgG in the pres-
ence of 10 μg/ml SSL10.
Transfection of CXCR4 in HEK Cells
CXCR4 was cloned into pABC-intra1-hisN-TEV, a mammalian ex-
pression vector that contains the CMV promoter from plasmid pCI
(Promega, Madison, WI), OriP from pCEP4 (Invitrogen), the origin
of replication and the β-lactamase gene of pcDNA3.1 (Invitrogen),
and an expression cassette [29]. The expression cassette consists of a
Kozak sequence, followed by an ATG codon, a HIS-tag, and a TEV-
protease cleavage site, an in-frame BamHI-NotI cloning site, and an in-
frame stop codon. A PCR was performed, which replaced the start
methionine of CXCR4 by a BglII restriction site and the stop codon
by a NotI restriction site. After confirmation of the sequence, CXCR4
was cloned into BamHI-NotI–digested pABC-intra1-(HIS)N-TEV,
generating plasmid pABC-intra1-HIS(N)-TEV-CXCR4. Recombi-
nant CXCR4 was produced in suspension growing HEK293EBNA1
cells by transient transfection. To this end, 2 μg of plasmid pABC-
intra-HIS(N)-TEV-CXCR4 was complexed with 4 μg of polyethyl-
eneimine in 100 μl of OptiMEM (Invitrogen).
After 10 minutes of incubation at room temperature, the DNA-
polyethyleneimine complex was added to 4 ml of HEK293EBNA1
cells at 0.7 × 106 cells/ml. Cells were harvested by gentle centrifu-
gation 48 hours after transfection, washed with RPMI/HSA, and
incubated with the 2 μg/ml anti-HIS mAb (VWR International,
Amsterdam, the Netherlands) and 30 μg/ml SSL10-FITC, and sub-
sequently with 2 μg/ml APC-labeled goat antimouse Ig (PharMingen,
San Diego, CA). Cells were washed and assayed on a flow cytometer,
after addition of propidium iodide, for binding of SSL10-FITC to the
CXCR4-expressing (APC-positive) and propidium iodide–negative
cells (living) cells. In other experiments, HEK293EBNA1 cells express-
ing the CXCR4 were used to test whether SSL10 could compete
with the binding of PE-labeled anti-CXCR4 mAb 12G5. Therefore,
the cells were incubated with 2 μg/ml anti-HIS mAb, 2 μg/ml APC-
labeled goat antimouse Ig, and 0 or 30 μg/ml SSL10 with washing
steps in between. Finally, the cells were incubated with PE-labeled anti-
CXCR4 mAb 12G5. After washing, the binding of PE-labeled anti-
CXCR4 mAb was analyzed to CXCR4-expressing (APC-positive) cells.
Calcium Mobilization Assay
The effect of SSL10 on CXCL12-induced intracellular calcium re-
lease in Jurkat cells was measured in a flow cytometer, as described
before [21]. Briefly, cells (5 × 106 cells/ml) were loaded with 2 μM
Fluo-3-AM (Molecular Probes Europe, Leiden, the Netherlands) in
RPMI/HSA for 20 minutes at room temperature, protected from
light, and kept under constant agitation. Next, cells were washed with
buffer and suspended to 1 × 106 cells/ml in RPMI/HSA. Subsequently,
Fluo-3–labeled cells were preincubated with buffer or 10 μg/ml
SSL10 for 1 minute at room temperature. Cells (1 × 106 cells/ml)
were monitored for calcium mobilization over time, first for 10 sec-
onds to determine the basal fluorescence level and then for 40 seconds
after stimulation with CXCL12 (3 × 10−10 to 3 × 10−8 M). Fluores-
cence was measured using a flow cytometer. The effect of SSL10 on
CXCL12, CXCL8, and C5a-induced calcium mobilization in human
neutrophils was also tested using the same method. Data are displayed
as percentage of maximal calcium mobilization using the following
formula: ((X MF − bg MF)/(Maximal MF − bg MF)) × 100%, in
which X MF = measured mean fluorescence; bg = background. For
the maximal MF, the MF value of cells stimulated with the highest
concentration of stimulus was used. For all stimuli, calcium mobiliza-
tion was determined at 5 seconds after stimulation. To study CXCL12-
induced calcium mobilization in SupT1 cells, cells were labeled with
2 μM Fura-2-AM (Molecular Probes Europe) for 45 minutes at room
temperature, washed and resuspended in Hank’s balanced salt solution
containing 25 mM HEPES and 0.1% HSA (HBSS/HEPES/HSA) at
7.5 × 106 cells/ml. Cells were transferred into black clear-bottom mi-
crotiter plates and were preincubated with buffer or 10 μg/ml SSL10
for 1 minute at room temperature. Subsequently, the fluorescence was
measured every 2 seconds at dual-excitation wavelengths of 340 and
380 nmwith 510 nm emission in a fluorescent plate reader (FlexStation;
Molecular Devices, Sunnyvale, CA). CXCL12 (final concentration,
10−8 M) was automatically added after 30 seconds of baseline reading,
and measurement continued for an additional 3 minutes. The ratio of
340:380 was calculated for every reading and plotted versus time.
Chemotaxis and Migration
Chemotaxis of Jurkat cells toward CXCL12 was measured in a
96-well chemotaxis chamber (ChemoTX; NeuroProbe, Gaithersburg,
MD) using an 8-μm pore size polycarbonate membrane. Cells (5 ×
106/ml) were labeled with 2 μM calcein-AM for 20 minutes at room
temperature protected from light. Subsequently, cells were washed
with HBSS/HSA, resuspended to 2.5 × 106 cells/ml, and incubated
with SSL10 (1-10 μg/ml). Dilutions of CXCL12 (1 × 10−11 to 3 ×
10−8 M) were prepared in HBSS/HSA, and 29 μl was placed into
each well of the lower compartment of the chamber in triplicate.
Wells with the control medium were included to measure the spon-
taneous cell migration. For total cell fluorescence, wells were filled
with 25 μl of labeled cells plus 4 μl of buffer. The membrane holder
was assembled, and 25 μl of labeled cells was added as a droplet to
each upper well except for the total fluorescence wells. The plate was
incubated for 30 minutes at 37°C in a humidified 5% CO2 atmo-
sphere. The membrane was washed extensively with PBS, and the
fluorescence of the wells was measured in a fluorescent plate reader
(FlexStation) with excitation at 485 nm and emission at 530 nm.
The percentage of chemotaxis was calculated relative to the fluores-
cence value of cells added directly to the lower well: (fluorescence
sample / fluorescence total counts) × 100. SSL10 was also tested on
CXCL8- and C5a-induced chemotaxis of human neutrophils using
the same method. To test the effect of SSL10 on the migration of ad-
herent HeLa cells, 24-well Transwell plates (Costar 3422, Cambridge,
MA) were used. The polyvinylpyrrolidone-free polycarbonate fil-
ters with an 8-μm pore size were precoated overnight at 4°C with
1% BSA in PBS. HeLa cells (6.5 × 105 cells/ml) were resuspended
in DMEM, containing 1% FCS/0.1% BSA, and preincubated with
medium alone or medium with 10 μg/ml SSL10 for 10 minutes at
37°C. Then, 150 μl of cells was added to the upper chamber, whereas
300 μl of medium alone or medium with CXCL12 (1 × 10−9 M) was
added to the lower compartment of the Transwell system. Cells were
allowed to migrate for 24 hours at 37°C. After incubation, the non-
migrated cells remaining on the upper side of the filter were gently
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removed using cotton-tipped swabs. Subsequently, cells on the lower
surface of the filter were fixed in 75% methanol/25% acetic acid
and stained with 0.25% Coomassie brilliant blue in 45% methanol/
10% acetic acid. Ten high-power fields (×400) were counted under a
light microscope, and the results were expressed as the mean number
of migrated cells.
Western Blot Analysis
Jurkat or A2780 (106) cells were cultured in RPMI-1640 (without
FCS) for 24 hours. After the indicated treatments, cell lysates were
prepared with a sample buffer (25 mM Tris-HCl, 5% wt/vol glycerol,
1% wt/vol SDS, and 0.05% wt/vol bromophenol blue, pH 6.8).
Subsequently, lysates were subjected to SDS-PAGE and transferred to
Immobilon-P membranes (Millipore, Bedford, MA). Blots were probed
by primary antibodies against protein kinase B/Akt and phospho-Akt
and then treated with horseradish peroxidase–conjugated secondary
antibodies (Dako). Enhanced chemiluminescence was used for final
signal detection.
Results
SSL10 Competes with the Binding of Antibody Directed
against CXCR4 on T cells
A screening assay to identify a bacterial inhibitor for surface-
expressed CXCR4 was performed with the hematopoietic Jurkat
T cell line. For this purpose, 11 excreted staphylococcal proteins,
namely, SSL6, SSL7, SSL8, SSL10, SSL11, SCIN-A, -B, -C, Orf-D,
FLIPr, and CHIPS, were tested for their ability to block the binding
of the function-blocking anti-CXCR4 mAb 12G5. SSL10 clearly
blocked the binding of the anti-CXCR4 mAb (Figure 2A), whereas
the other S. aureus proteins showed no effect (data not shown). In
Figure 2B, the dose-dependent inhibition of anti-CXCR4 mAb bind-
ing by SSL10 is depicted, showing that 10 μg/ml SSL10 decreased
anti-CXCR4 mAb binding by 80%. Sialic acid residues were earlier
shown to be critical determinants in the recognition of surface recep-
tors by SSL5 and SSL11 [30,31]. To examine the role of sialic acids
in the SSL10/CXCR4 interaction, Jurkat cells were first treated with
neuraminidase. Upon treatment, no effect on SSL10-induced inhibi-
tion of anti-CXCR4 mAb binding was observed, showing that sialyl
Lewis X sugars do not play a role in the binding of SSL10 to CXCR4
(Figure 2B). Same effects of SSL10 on anti-CXCR4 mAb binding with
and without neuraminidase treatment were shown for the hemato-
poietic SupT1 T-cell line (data not shown).
SSL10 Binds to Jurkat and CXCR4-Transfected HEK Cells
The SSL10-mediated blocking of the anti-CXCR4 mAb binding
to Jurkat cells could be indicative of binding of SSL10 to CXCR4.
We used SSL10-FITC and flow cytometry to confirm binding to
CXCR4-expressing Jurkat cells (Figure 2C ). To exclude for an aspecific
effect of SSL10 on mAb binding to cells, also the binding of other
mAbs was studied. Figure 1D shows that there was no inhibition of
anti-CD3 mAb binding to Jurkat cells by SSL10 and that there was no
effect on the binding of anti-CXCR1 and anti-C5aR mAbs to human
neutrophils. To further confirm specific binding of SSL10 to CXCR4,
we transiently transfected HEK293EBNA1 cells with CXCR4. SSL10
specifically bound to CXCR4-transfected compared with nontrans-
fected HEK293EBNA1 cells (Figure 2E). Also, binding of anti-CXCR4
mAb to CXCR4-expressing HEK293EBNA1 cells was inhibited by
SSL10 (Figure 2F). Thus, SSL10 was identified as a specific CXCR4-
binding protein.
SSL10 Inhibits CXCL12-Induced Calcium Mobilization
The hallmark of chemokine receptors is a rapid and transient in-
crease in the free intracellular calcium level on ligand binding. This
signaling pathway was used to examine whether SSL10 not only binds
CXCR4 but also inhibits the activation by its natural ligand CXCL12.
Figure 3A demonstrates that SSL10 inhibited the CXCL12-induced
calcium mobilization in Jurkat cells. This effect was not cell type–
specific as SSL10 also clearly inhibited the CXCL12-induced calcium
mobilization in SupT1 cells (Figure 3B) and neutrophils (Figure 3C).
SSL10, used as a stimulus up to 30 μg/ml, did not evoke calcium mo-
bilization itself (data not shown). Calcium mobilization induced by
ionomycin and ATP was not affected by SSL10 excluding toxic effects
on the cells (data not shown). In control experiments with human
neutrophils, SSL10 did not inhibit CXCL8- or C5a-induced calcium
responses (Figure 3, D and E). These data show that SSL10 is highly
specific toward the CXCR4 receptor.
SSL10 Is Not Internalized after Binding CXCR4
Thus far, we found that SSL10 inhibits binding of anti-CXCR4
mAb at 0°C. This suggests that SSL10 exerts its effect on CXCL12-
induced calcium mobilization outside the cells, apparently indepen-
dent of cell signaling events. To further address this, we determined
the possible internalization of SSL10 by Jurkat cells. As a control,
FITC-labeled formylated peptide was used, which has been described
to be internalized after binding the FPR on neutrophils [23]. Figure 4A
shows that SSL10-FITC remains outside the Jurkat cells, whereas in
neutrophils, the FITC-labeled formylated peptide is internalized (data
not shown). These results strongly indicate that SSL10 affects CXCR4
directly, independently of its signaling events or internalization.
SSL10 Inhibits CXCL12-Induced Phosphorylation of Akt
By using Western blot analysis, we further examined CXCL12/
CXCR4–induced activation of Akt, a pathway associated with cell sur-
vival. As shown in Figure 4B, we observed a rapid increase in the phos-
phorylation of Akt in Jurkat cells on stimulation with CXCL12. Akt
phosphorylation was inhibited by AMD3100, a bicyclam antagonist of
CXCR4, and, to a lesser extent, by SSL10. The combination of both
CXCR4-inhibiting agents showed a synergistic effect of this inhibiting
capacity. Neither the CXCR4-negative cell line A2780 nor SSL10
showed CXCL12-induced phosphorylation of Akt (Figure 4C ).
SSL10 did not influence the viability of Jurkat cells, as they were
still 97% viable after 24 hours of incubation with 10 μg/ml SSL10 at
37°C, as verified by trypan blue exclusion. Furthermore, SSL10 did
not influence cell proliferation of Jurkat cells as measured by MTT
assay (data not shown).
SSL10 Inhibits CXCL12-induced Cell Migration
We examined the ability of SSL10 to inhibit the CXCL12-
induced chemotaxis of Jurkat cells. Figure 5A shows that SSL10
clearly inhibits the chemotactic response of Jurkat cells toward
CXCL12, whereas background chemotaxis toward buffer was not
affected. As a control, CXCL8- and C5a-induced chemotaxis of
human neutrophils was not affected by SSL10 (Figure 5, B and C ).
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Figure 2. SSL10 binds CXCR4. (A) CXCR4-expressing Jurkat T-ALL cells were incubated with or without 10 μg/ml SSL10 for 30 minutes on
ice. After washing, cells were stained with anti-CXCR4 mAb and detected with FITC-conjugated goat antimouse IgG. Continuous and
dashed black lines represent untreated and SSL10-treated cells, respectively. Gray histogram represents control-stained cells. Data are
one representative example of three independent experiments. (B) Jurkat cells were treated with (black bars) or without (open bars) neur-
aminidase before incubation with SSL10 (1-10 μg/ml) for 30 minutes on ice. After washing, cells were stained with anti-CXCR4 mAb that
was detected with FITC-conjugated goat antimouse IgG. Data represent mean fluorescence values ± SEM of three independent experi-
ments. (C) Jurkat cells were incubated with (black line) or without (gray histogram) 10 μg/ml SSL10-FITC for 30 minutes on ice before
analysis on a flow cytometer. Data are one representative example of three independent experiments. (D) Jurkat cells were incubated with
10 μg/ml SSL10 for 30 minutes on ice. After washing, the cells were stained for CXCR4 and CD3 expression. In separate experiments,
neutrophils were stained for CXCR1 and C5aR expression. Data represent the relative binding of each antibody compared with untreated
cells and are mean values ± SEM of three independent experiments. (E) HEK293EBNA1 cells were transfected with CXCR4. N-terminally
HIS-tagged CXCR4 expression was detected by staining with anti-HIS mAb and APC-labeled goat antimouse IgG. Transfected HEK cells
were incubated with 30 μg/ml SSL10-FITC for 30 minutes on ice before analysis on a flow cytometer. Data represent SSL10-FITC binding to
CXCR4-expressing (APC-positive; black line) and untransfected (APC-negative; gray histogram) HEK cells. Data are one representative ex-
ample of three independent experiments. (F) CXCR4-transfected HEK293EBNA1 cells were incubated with anti-HIS mAb and APC-labeled
goat antimouse IgG. Then, the effect of 30 μg/ml SSL10 on the binding of PE-labeled anti-CXCR4 mAb was analyzed to CXCR4-expressing
(APC-positive) cells. Data represent isotype mAb (gray histogram) and PE-labeled anti-CXCR4 mAb binding with (dotted line) or without
(black line) preincubation of SSL10. Data are one representative example of three independent experiments.
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Figure 3. SSL10 specifically inhibits CXCL12-induced calcium mobilization. (A) The effect of SSL10 on intracellular calcium release in-
duced by CXCL12 (10−7 to 10−10 M) in Fluo-3–loaded Jurkat cells was determined using flow cytometry. After preincubating cells with
10 μg/ml SSL10 (▪) or buffer (•), the basal fluorescence level was measured for each sample before CXCL12 was added. Activation ofcontrol cells stimulated with the highest concentration of stimulus was set to 100% to display relative calcium mobilization values on the
y-axis. Data represent mean values ± SEM of three independent experiments. (B) Representative experiment showing CXCL12 (10−8 M)
induced calcium mobilization in Fura-2–loaded SupT1 cells treated with buffer or 10 μg/ml SSL10. Results are depicted as the ratio of the
fluorescence at 530:590 nm measured in a fluorescent plate reader. (C–E) Effect of SSL10 on the calcium mobilization in neutrophils
induced by CXCL12 (10−7 to 10−9 M) (C), CXCL8 (10−9 to 10−12 M) (D) and C5a (10−8 to 10−11 M) (E). Experimental details as described
under (A).
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These results are in agreement with our data on receptor expression
and calcium mobilization experiments. CXCR7 is a recently discov-
ered deorphanized G-protein–coupled receptor that binds CXCL11
and CXCL12 with high affinity [32]. To investigate whether SSL10
might also affect CXCL12-induced migration through CXCR7 bind-
ing, SSL10 was tested for its ability to compete with the binding of the
blocking anti-CXCR7 mAb clone 11G8. We could not detect binding
of anti-CXCR7 mAb to Jurkat cells, already indicating that CXCR7
plays no role in the CXCL12-induced migration of Jurkat cells. To
further exclude SSL10 effects through CXCR7, we tested cervical car-
cinoma HeLa cells, which are described to express CXCR7 [32].
Figure 6A shows clear binding of blocking anti-CXCR7 mAb 11G8
to HeLa cells. This could not be inhibited by SSL10, suggesting that
SSL10 does not bind CXCR7 (Figure 6A). In contrast, binding of
anti-CXCR4 mAb 12G8 to HeLa was clearly inhibited by SSL10
(Figure 6B). More importantly, SSL10 completely inhibited the
CXCL12-induced migration of HeLa cells (Figure 6C).
Discussion
The aim of this study was to identify bacterial antagonists for
CXCR4 that prevent malignant cell behavior. We identified SSL10
as a strong inhibitor of CXCR4, as exemplified by CXCR4-expressing
human T-ALL, lymphoma, and cervical carcinoma cell lines. SSL10
inhibited CXCL12-induced responses at different levels of the various
involved signal transduction pathways, as shown by the inhibition of
CXCL12-induced calcium mobilization, Akt phosphorylation, and
migration. These results prove our hypothesis that bacterial proteins
targeting chemokine receptors on leukocytes can be used to inhibit
malignant cell migration.
Beneficial effects of bacterial infections on cancer prognosis are
known for a long time. About 100 cases of spontaneous remission
of acute leukemia after recovery from sepsis has been described
[33,34]. The mechanisms inducing spontaneous remission are
thought to be related with an overwhelming immune response lead-
ing to raised levels of various cytokines that cause an increased acti-
vation of the immune system. An alternative explanation would be
that bacteria directly target chemokine receptors on innate immune
cells primarily to prevent clearance by these cells, and additionally,
they target identical receptors on cancer cells. Thereby, they influ-
ence their malignant behavior resulting in spontaneous remission
of cancer.
A number of examples of bacterial proteins targeting non–cancer-
related chemokine receptors exist. In the past few years, we found
CHIPS and FLIPr, S. aureus proteins interfering with host cell mi-
gration through specific binding to the C5aR, FPR, and FPRL-1
[21,26]. Recently, the structure of CHIPS consisting of residues 31
to 121 (CHIPS31-121) was resolved [25]. CHIPS31-121 is composed
of an α-helix packed onto a four-stranded antiparallel β-sheet and is
found highly structural homologous to the C-terminal domain of
SSL5 and SSL7. SSLs are a family of secreted proteins identified
through sequence homology to staphylococcal and streptococcal
superantigens. SSL1 to SSL11 are encoded on staphylococcal patho-
genicity island 2 present in all S. aureus strains, whereas SSL12 to
SSL14 are found on immune evasion cluster [35,36]. Analysis of
Figure 4. SSL10 is not internalized on binding and inhibits CXCL12-induced phosphorylation of Akt. (A) Jurkat cells were incubated with
10 μg/ml SSL10-FITC in RPMI/HSA at 37°C. At different time points, SSL10-FITC binding was measured in a flow cytometer before and
immediately after addition of 300 μg/ml trypan blue to discriminate between ligand binding on the outside the cell measured as total
SSL10-FITC binding (•) and internalized ligand (▪). Data are expressed as fluorescence values and are the mean ± SEM of three separateexperiments. (B) Representative experiment of effects of SSL10 on CXCL12-induced phosphorylation of Akt and total Akt in Jurkat cells
determined by Western blot analysis. Cells were incubated with buffer, 25 μg/ml AMD3100, 20 μg/ml SSL10, or both for 20 minutes
at room temperature before treatment (30 minutes of incubation at 37°C) with buffer or CXCL12 (10−7 M). (C) Effects SSL10 on
CXCL12-induced phosphorylation of Akt and total Akt in CXCR4-negative A2780 cells as determined by Western blot analysis.
340 SSL10 Inhibits Tumor Cell Migration Walenkamp et al. Neoplasia Vol. 11, No. 4, 2009
the degree of polymorphism among SSL proteins reveals 22% to
65% identity, whereas allelic variations among SSL proteins varies
between 54% and 100% [31,35]. Thus far, no relevant sequence ho-
mologies with other bacterial proteins are known. Determination of
the crystal structures of SSL5 and SSL7 also revealed their high struc-
tural homology to superantigens; the N-terminal oligonucleotide/
oligosaccharide–binding fold and the C-terminal β-grasp domain
characteristic for superantigens are also observed in SSLs. However,
residues important for MHC class II and T cell receptor (TCR) bind-
ing of superantigens are not conserved in SSLs, which may explain
their inability to display superantigenic activities. Three proteins of
the SSL family are thus far functionally described: SSL7 binds IgA
and complement C5 and inhibits IgA-Fc αRI binding and serum
killing of bacteria [37]. SSL5 inhibits P-selectin–mediated neutrophil
rolling by binding P-selectin glycoprotein ligand 1 [30]. SSL5 binding
to P-selectin glycoprotein ligand 1 was found to be dependent on the
presence of sugar moieties. SSL11 was also shown to interact with sLex
[31]. Unlike SSL5, SSL10 specifically binds the CXCR4 independent
of the presence of sugar moieties. Other bacterial products have been
described to target GPCRs, such as cholera and pertussis toxin that
covalently modify the α subunits of numerous G proteins by ADP-
ribosylating specific amino acid residues [38]. Staphylococcal super-
antigens stimulation of human peripheral blood monocytes results in
a rapid, dose-dependent, and specific down-regulation of CCR1,
CCR2, and CCR5, which correlates with a concomitant hyporespon-
siveness of human monocytes to these CC chemokine ligands [39].
Lipopolysaccharide causes a drastic and rapid down-regulation of the
expression of CCR2 [40] and is able to down-modulate CXCR4
in neutrophils and monocytes [41]. Like CHIPS, SSL10 probably
interferes with its GPCR through specific binding, as it competed
with anti-CXCR4 mAb binding at 0°C. Moreover, it remained outside
the cells when incubated at 37°C. These results strongly suggest that
SSL10 affects the CXCR4 directly, independently of its signaling events
or internalization.
For a long time, CXCR4 was described as the sole receptor for
CXCL12. Recently, an additional CXCL12-binding chemokine re-
ceptor, CXCR7, was identified [32]. Despite its high affinity for
CXCL12, the role of CXCR7 in chemotaxis is still a matter of debate.
Although one study claims that CXCR7 is involved in chemotaxis
[42], more recent data show that CXCR7 lacks intrinsic chemotactic
activity toward its ligand CXCL12 [32,43,44]. Our data support the
latter because CXCL12-induced migration of HeLa cells could not be
inhibited by the blocking anti-CXCR7 mAb 11G8 (data not shown).
As SSL10 did not compete with the binding of anti-CXCR7 mAb
Figure 5. SSL10 inhibits cell migration of Jurkat cells toward CXCL12. (A) Jurkat cells were allowed to migrate toward a concentration
range of CXCL12 (10−7 to 10−11 M) after incubation of cells with buffer (•), 1 μg/ml SSL10 (▴), or 10 μg/ml (▪) SSL10. (B and C) Migra-tion of human neutrophils toward a concentration range of C5a (B) and CXCL8 (C), after incubation of the cells with buffer (•) or10 μg/ml SSL10 (▪). Data are expressed as the percentage of migrated cells added to the upper compartment of the 96-well chemotaxis
chamber and are mean values ± SEM of four (A) and three (B and C) independent experiments.
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11G8 to CXCR7, SSL10 only antagonizes CXCR4 for inhibition of
CXCL12-induced responses.
The acquired ability of a localized tumor to metastasize is a multistep
process involving many pathways, including those involved in angio-
genesis, focal adhesion, invasion, and eventually colonization of a distant
site [45]. CXCR4 inhibitors may have, like other inhibitors targeting
malignant cell migration [46], a role in advanced disease, but even if
no activity is observed in this setting, their role in invasion and metastasis
might still enable a potential role in the adjuvant setting to reduce the risk
of recurrence after definitive therapy. Further studies are necessary to iden-
tify potential combinations that will be of benefit including combinations
with cytotoxic chemotherapy agents in the frontline setting and after the
development of resistance. Recent findings indicate that SDF-1α/
CXCR4 interactions contribute to the resistance of leukemic cells to
signal transduction inhibitor– and chemotherapy-induced apoptosis in
systems mimicking the physiological microenvironment [47]. Dis-
ruption of these interactions with CXCR4 inhibitors represents a novel
strategy of sensitizing leukemic cells by targeting their protective bone
marrow microenvironment.
CXCR4 is the most widely expressed chemokine receptor in many
different hematological and solid cancers and has been associated with
cancer dissemination and poor prognosis. Interfering with the chemo-
kine system would add possible treatment options for this poor prog-
nosis patient group. Since the disclosure of CXCR4 as a coreceptor
for human immunodeficiency virus, various CXCR4 antagonists have
been developed, including the horseshoe crab protein polyphemusin II
and its analogues [15,48–50], the small-molecule heterocyclic bicyclam
AMD3100 [51], and the monocyclam AMD3465 [52]. AMD3100
was originally developed as a CXCR4 inhibitor with anti–human im-
munodeficiency virus 1 activity but was withdrawn from the phase 2
clinical trial primarily because of a lack of antiviral effect and the occur-
rence of unexplained cardiotoxicity. AMD3100 was further developed
for stem cell mobilization and is now under evaluation in phase 3 clini-
cal studies for mobilization of hematopoietic stem cells (ClinicalTrials.
gov) and in preclinical studies as anticancer agent and treatment of
autoimmune disease.
Yet, bacteria provide us with evolutionary tailored, highly specific,
chemokine receptor inhibitors. SSL10 is the first example of such a
Figure 6. SSL10 does not bind CXCR7 and inhibits CXCL12-induced migration of HeLa cells. (A and B) Binding of blocking anti-CXCR7
mAb 11G8 (A) and blocking anti-CXCR4 mAb 12G5 (B) to HeLa cells in the presence (dotted line) and absence (black line) of SSL10. Gray
histograms represent binding of isotype control mAbs. Data are a representative of one of three independent experiments. (C) Migration
of HeLa cells preincubated with buffer or 10 μg/ml SSL10 toward 1 × 10−9 M CXCL12 using 24-well Transwell plates. Data are ex-
pressed as number of migrated cells counting five high-power field (×400) ± SEM of four independent experiments.
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protein interfering with malignant cell migration toward the CXCR4
ligand CXCL12. SSL10 could potentially serve as a supplement to
direct cytotoxic therapy to suppress cancer metastasis.
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